A search for 4750- and 4765-MHz OH masers in Southern Star Forming Regions

We have used the Australia Telescope Compact Array (ATCA) to make a sensitive (5-$\sigma$ $\simeq$ 100 mJy) search for maser emission from the 4765-MHz $^2\Pi_{1/2}$ F=1$\to$0 transition of OH. Fifty five star formation regions were searched and maser emission with a peak flux density in excess of 100 mJy was detected toward fourteen sites, with ten of these being new discoveries. In addition we observed the 4750-MHz $^2\Pi_{1/2}$ F=1$\to$1 transition towards a sample of star formation regions known to contain 1720-MHz OH masers, detecting marginal maser emission from G348.550-0.979. If confirmed this would be only the second maser discovered from this transition. The occurrence of 4765-MHz OH maser emission accompanying 1720-MHz OH masers in a small number of well studied star formation regions has lead to a general perception in the literature that the two transitions favour similar physical conditions. Our search has found that the presence of the excited-state 6035-MHz OH transition is a much better predictor of 4765-MHz OH maser emission from the same region than is 1720-MHz OH maser emission. Combining our results with those of previous high resolution observations of other OH transitions we have examined the published theoretical models of OH masers and find that none of them predict any conditions in which the 1665-, 6035- and 4765-MHz transitions are simultaneously inverted. Erratum abstract: Dodson & Ellingsen (2002) included several observations with significant pointing errors, invalidating the upper limits found in these directions. These have now been reobserved or recalculated. A new table of upper limits has been generated, and two more masers that would have been seen have been found.Comment: Included an Erratum with Max as another author. This erratum was rejected by MNRAS (Feb 04) as it contained too much data. Resubmitted as a paper (Jun 04). Rejected (Sep 04) it had too little data. Resubmitted as reduced erratum (Apr 05). Still waitin

Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration

© 2017, © The Author(s) 2017. Background. Guidelines surrounding optimum needle retention duration in acupuncture have not been established, despite a growing evidence base for acupuncture over recent decades. This retrospective study explored the effect of varying acupuncture needle retention durations in cancer patients. Method. Patients received either 2 (n = 35), 10 (n = 53), or 20 minutes (n = 54) of acupuncture once a week for 6 weeks. Outcomes of anxiety and depression, stress, fatigue, and quality of life (QOL), with the Hospital Anxiety and Depression Scale, Perceived Stress Scale, Functional Assessment of Cancer Therapy–Fatigue, and European Organization for Research and Treatment of Cancer Quality of Life, were measured at baseline and at 6 weeks following the intervention. Results. The mean age of participants was 58 years (n = 152). The majority were female, diagnosed with breast cancer. Depression, stress, fatigue, and QOL were significantly improved in all 3 groups at 6 weeks postintervention. No significant differences in all outcomes were found between the 3 groups (≤2 vs 10 minutes vs 20 minutes). There were no differences with the satisfaction of the acupuncture services and perceived efficacy of acupuncture among the 3 groups. More than 95% of participants indicated that they would recommend acupuncture to other cancer patients, friends, and their family members. Conclusion. The efficacy of acupuncture may not only depend on needle retention duration, but may also be associated with multiple factors. Considering the limitations of this study design, robust randomized controlled studies are warranted to confirm the findings

Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.

To report clinician-perceived changes to cancer service delivery in response to COVID-19. Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology. Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution. Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%). Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians. Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large

The tails in the Helix Nebula NGC 7293

We have examined a stream-source model for the production of the cometary tails observed in the Helix Nebula NGC 7293 in which a transonic or moderately supersonic stream of ionized gas overruns a source of ionized gas. Hydrodynamic calculations reveal velocity structures which are in good agreement with the observational data on tail velocities and are consistent with observations of the nebular structure. The results also are indicative of a stellar atmosphere origin for the cometary globules. Tail remnants persist for timescales long enough for their identification with faint striations visible in the nebula gas to be plausible.Comment: 7 pages, 6 figures, accepted for publication in A&

Methanol and excited OH masers towards W51: I - Main and South

MERLIN phase-referenced polarimetric observations towards the W51 complex were carried out in March 2006 in the Class II methanol maser transition at 6.668 GHz and three of the four excited OH maser hyperfine transitions at 6 GHz. Methanol maser emission is found towards both W51 Main and South. We did not detect any emission in the excited OH maser lines at 6.030 and 6.049 GHz down to a 3 sigma limit of ~20 mJy per beam. Excited OH maser emission at 6.035 GHz is only found towards W51 Main. This emission is highly circularly polarised (typically 45% and up to 87%). Seven Zeeman pairs were identified in this transition, one of which contains detectable linear polarisation. The magnetic field strength derived from these Zeeman pairs ranges from +1.6 to +6.8 mG, consistent with the previously published magnetic field strengths inferred from the OH ground-state lines. The bulk of the methanol maser emission is associated with W51 Main, sampling a total area of ~3"x2.2" (i.e., ~16200x11900 AU), while only two maser components, separated by ~2.5", are found in the W51 South region. The astrometric distributions of both 6.668-GHz methanol and 6.035-GHz excited-OH maser emission in the W51 Main/South region are presented here. The methanol masers in W51 Main show a clear coherent velocity and spatial structure with the bulk of the maser components distributed into 2 regions showing a similar conical opening angle with of a central velocity of ~+55.5 km/s and an expansion velocity of =<5 km/s. The mass contained in this structure is estimated to be at least 22 solar masses. The location of maser emission in the two afore-mentioned lines is compared with that of previously published OH ground-state emission. Association with the UCHII regions in the W51 Main/South complex and relationship of the masers to infall or outflow in the region are discussed.Comment: 19 pages, 16 figures and 4 tables, accepted for publication in MNRA

Multiwavelength observations of the supernova remnant G349.7+02 interacting with a molecular cloud

We present molecular-line observations at millimetre, centimetre and infrared wavelengths of the region containing OH(1720 MHz) masers in the supernova remnant (SNR) G349.7+0.2, using the Australia Telescope (AT) Mopra antenna, the Swedish-ESO Submillimeter Telescope, the AT Compact Array and the UNSW Infrared Fabry-Perot narrow-band filter installed on the Anglo-Australian Telescope. Several molecular transitions were observed between 1.6 and 3 mm to constrain the physical parameters of the molecular cloud interacting with the SNR and to investigate the effects of the SNR shock on the gas chemistry. We detected shock-excited near-infrared H2 emission towards the centre of the SNR, revealing highly clumped molecular gas and a good correlation with published mid-infrared images from the Spitzer Space Telescope. An excellent correlation between the H2 clumps and OH(1720 MHz) maser positions supports the shock excitation of the OH(1720 MHz) maser emission. Furthermore, we detected OH absorption at 1665 and 1667 MHz which shows a good correlation with the shocked H2 emission and the masers. We found maser emission at 1665 MHz near the OH(1720 MHz) masers in this SNR, which is found to be associated with a GLIMPSE source SSTGLMC G349.7294+00.1747. We also detected 1665 and 1667 MHz OH masers, and weak 4.8 GHz H2CO absorption towards the ultracompact HII region IRAS 17147-3725 located to the southeast of the SNR. We found no 4.7- or 6-GHz excited-state OH masers or 6-GHz CH3OH maser towards either the SNR or the HII region.Comment: 25 pages, 13 figures, published in MNRA

DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication

AbstractDNA vaccines and recombinant Listeria monocytogenes that express and secrete SIV Gag and Env antigens were combined in a nonhuman primate prime-boost immunogenicity study followed by a challenge with SIV239. We report that recombinant DNA vaccine delivered intramuscularly, and recombinant L. monocytogenes delivered orally each individually have the ability to induce CD8+ and CD4+ T cell immune responses in a nonhuman primate. Four rhesus monkeys were immunized at weeks 0, 4, 8, and 12 with the pCSIVgag and pCSIVenv DNA plasmids and boosted with SIV expressing L. monocytogenes vaccines at weeks 16, 20, and 28. Four rhesus monkeys received only the L. monocytogenes vaccines at weeks 16, 20, and 28. A final group of monkeys served as a control group. Blood samples were taken before vaccination and 2 weeks post each injection and analyzed by ELISPOT for CD4+ and CD8+ T cell responses. Moderate vaccine induced SIV-specific cellular immune responses were observed following immunization with either DNA or L. monocytogenes vectors. However, the SIV antigen-specific immune responses were significantly increased when Rhesus macaques were primed with SIV DNA vaccines and boosted with the SIV expressing L. monocytogenes vectors. In addition, the combined vaccine was able to impact SIV239 viral replication following an intrarectal challenge. This study demonstrates for the first time that oral L. monocytogenes can induce a cellular immune response in a nonhuman primate and is able to enhance the efficacy of a DNA vaccine as well as provide modest protection against SIV239 challenge

Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report

<p>Abstract</p> <p>Introduction</p> <p>Gout is a common inflammatory arthritis caused by articular precipitation of monosodium urate crystals. It usually affects the first metatarsophalangeal joint of the foot and less commonly other joints, such as wrists, elbows, knees and ankles.</p> <p>Case presentation</p> <p>We report the case of a 75-year-old Caucasian man with tophaceous multiarticular gout, soft-tissue involvement and ulcerated tophi on the first metatarsophalangeal joint of the left foot, on the first interphalangeal joint of the right foot and on the left thumb.</p> <p>Conclusion</p> <p>Ulcers due to tophaceous gout are currently uncommon considering the positive effect of pharmaceutical treatment in controlling hyperuricemia. Surgical treatment is seldom required for gout and is usually reserved for cases of recurrent attacks with deformities, severe pain, infection and joint destruction.</p